Investment
Features
FeesSafety
Academy
More
Pluang+

Wealth adviser predicts 100x Bitcoin gains, urges clients to acquire one BTC now

Analyst Insights
19 Oct 2026
Tokenpost
View Source
Neutral
Wealth adviser predicts 100x Bitcoin gains, urges clients to acquire one BTC now

A video shared by The Bitcoin Historian quotes an unnamed wealth adviser who encourages clients to obtain one Bitcoin, believing it could increase in value by 100 times. The adviser also notes that institutional adoption and understanding of Bitcoin remain limited. However, no specific timeframe or price target was provided for this optimistic outlook. This reflects a personal opinion rather than a confirmed market trend or institutional demand measurement.

Bitcoin's 100-fold value view is noted here with Pluang's market data for context. As of Oct 20, 2026 09:21 WIB, 15 of 50 major cryptocurrencies rose and 34 fell. LINK priced Rp215.752 dropped 2.39%, AAVE at Rp2.691.656 fell 2.35% but had 100% buy orders, and CRV at Rp6.589 rose 2.20% with 99% sell orders.

More News

Anteris gets German clearance to expand global PARADIGM heart valve trial, boosting patient recruitment.

Anteris gets German clearance to expand global PARADIGM heart valve trial, boosting patient recruitment.

Anteris Technologies received regulatory approval from Germany's BfArM to start enrolling patients in its global PARADIGM trial for the DurAVR Transcatheter Heart Valve. This approval allows the company to recruit patients at leading German centers, ...

Market News
Bullish
2 hours ago
XBiotech's phase II trial shows 61.3% 12-month survival in refractory metastatic colorectal cancer with vilamakitug.

XBiotech's phase II trial shows 61.3% 12-month survival in refractory metastatic colorectal cancer with vilamakitug.

XBiotech announced positive final efficacy results from its phase II TASKIN trial for vilamakitug (XB2001) in refractory metastatic colorectal cancer. The study, funded by the French National Cancer Institute, showed a 61.3% overall survival rate at ...

Company Fundamentals
Bullish
4 hours ago
Phase II study shows Vilamakitug improves 12-month survival in refractory metastatic colorectal cancer.

Phase II study shows Vilamakitug improves 12-month survival in refractory metastatic colorectal cancer.

XBiotech announced positive final results from the Phase II TASKIN study, showing that adding Vilamakitug (XB2001) to standard chemotherapy improved 12-month overall survival to 61.3% in patients with refractory metastatic colorectal cancer, surpassi...

Market News
Bullish
4 hours ago
Solana's non-vote transactions hit 8.92B in Q3 2026, up 104% from Q4 2025, setting new weekly and monthly records.

Solana's non-vote transactions hit 8.92B in Q3 2026, up 104% from Q4 2025, setting new weekly and monthly records.

Solana recorded 8.92 billion non-vote transactions from July to September 2026, marking a 104% increase compared to the fourth quarter of 2025. These transactions exclude validator votes and include activities like transfers, trading, and decentraliz...

Protocol Fundamentals
Bullish
4 hours ago
Jio Platforms' IPO anchor book oversubscribed 30x with $26.3B bids from top global investors

Jio Platforms' IPO anchor book oversubscribed 30x with $26.3B bids from top global investors

Jio Platforms, backed by Meta and Google, has seen its IPO anchor book oversubscribed over 30 times, attracting $26.3 billion in bids for an $854 million portion. The company aims to raise up to $3.2 billion in India's largest-ever IPO by rupee value...

Market News
Bullish
4 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App